WNS Named to TIME's 2025 List of World's Most Sustainable Companies
TIME and market research company Statista collaborated to construct the 2025 list that evaluated shortlisted organizations, including WNS, on more than 20 key performance indicators. For this second edition of the 'World's Most Sustainable Companies', over 5,000 companies were assessed on sustainable business practices, commitments & ratings, reporting standards & transparency, and environmental & social stewardship to arrive at the final 500.
'We are honored to be featured in the 2025 TIME list of World's Most Sustainable Companies. This recognition underscores our continued commitment to creating lasting, sustainable value for all our stakeholders including clients, employees, investors, and the communities we serve,' said Keshav R. Murugesh, Group CEO, WNS.
Demonstrating its ongoing commitment to ethical and responsible business practices, WNS continues to drive continuous improvement in its sustainability efforts. WNS adheres to globally recognized frameworks including the Global Reporting Initiative (GRI) and Sustainability Accounting Standards Board (SASB) standards to deliver holistic and credible sustainability reporting. As a long-standing signatory to the United Nations Global Compact (UNGC), WNS aligns with the Ten Principles of the UNGC across human rights, labor, environment and anti-corruption. WNS has also conducted a comprehensive global Climate Risk Assessment aligned with Task Force on Climate-related Financial Disclosures (TCFD) and IFRS S2 standards, further integrating climate risk into its business strategy and company disclosures. Additionally, WNS has received validation of its Net-Zero emissions reduction targets by the Science Based Targets initiative (SBTi).
In 2024, WNS was awarded a Platinum Medal by EcoVadis for its sustainability programs, one of the highest distinctions in global business sustainability assessments. In addition, WNS has been included in the Dow Jones Best-in-Class Emerging Markets Index in 2024 and received top sustainability scores by several key sustainability rating institutions.
The full list of TIME's World's Most Sustainable Companies 2025 can be accessed here: https://time.com/collection/worlds-most-sustainable-companies-2025/ About WNS WNS (Holdings) Limited (NYSE: WNS) is a digital-led business transformation and services company. WNS combines deep domain expertise with talent, technology, and AI to co-create innovative solutions for over 700 clients across various industries. WNS delivers an entire spectrum of solutions including industry-specific offerings, customer experience services, finance and accounting, human resources, procurement, and research and analytics to re-imagine the digital future of businesses. As of March 31, 2025, WNS had 64,505 professionals across 64 delivery centers worldwide including facilities in Canada, China, Costa Rica, India, Malaysia, the Philippines, Poland, Romania, South Africa, Sri Lanka, Turkey, the United Kingdom, and the United States.
For more information, visit www.wns.com or follow us on Facebook, Twitter, LinkedIn, and Instagram.
Safe Harbor Provision This document includes information which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions as to future events. Factors that could cause actual results to differ materially from those expressed or implied are discussed in our most recent Form 10-K and other filings with the Securities and Exchange Commission. WNS undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
(Disclaimer: The above press release comes to you under an arrangement with Business Wire India and PTI takes no editorial responsibility for the same.).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
12 hours ago
- Economic Times
Is Novo Nordisk facing its 'Nokia moment'? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forces
Reuters Novo Nordisk, Denmark's pharma powerhouse, has seen its stock plunge from record highs as fierce competition, slowing growth, and market shifts test its dominance in the global diabetes and obesity drug market. Novo Nordisk (NYSE: NVO) closed at $50.39 on Thursday, down $0.51 (-1%), extending its staggering decline from a year-high of $139.74. Investors are questioning whether the Danish pharmaceutical giant is approaching its own 'Nokia moment'—a pivotal inflection point where market dominance is challenged by nimble competitors and shifting industry dynamics. On July 29, 2025, Novo Nordisk lowered its full-year 2025 sales growth forecast from 13–21% to 8–14%. Operating profit (EBIT) growth was also trimmed to 10–16% from 16–24%. The announcement triggered a 20–30% single-day stock plunge, wiping out roughly $70 billion in market capitalization. Investors had expected continued dominance in the lucrative obesity and diabetes markets, but the downgrade sent an unmistakable warning: growth is slowing, and the competitive landscape is shifting rapidly. Novo Nordisk's blockbuster drugs Wegovy and Ozempic have faced growing headwinds: Compounded versions from U.S. pharmacies —driven by FDA shortages—have eaten into branded sales. —driven by FDA shortages—have eaten into branded sales. Eli Lilly's Zepbound and Mounjaro are gaining prescription share. As of July 2025, Zepbound holds 59% of prescriptions compared to Wegovy's 40%, signaling a material shift in market preference. These trends highlight a dual threat: traditional competition and unregulated compounding pharmacies undermining pricing power. Longtime CEO Lars Fruergaard Jørgensen stepped down on August 7, 2025, passing the reins to Maziar Mike Doustdar. The new CEO faces immediate challenges: stabilizing sales, defending market share, and restoring investor confidence. Market watchers emphasize that leadership changes at such a sensitive moment can either signal a bold strategic pivot or deepen uncertainty, depending on how quickly Doustdar asserts his vision. Novo Nordisk is also navigating U.S. legal scrutiny. A class-action lawsuit claims the company misled investors about competitive risks and overstated growth prospects. Financial institutions are taking note: UBS downgraded NVO to 'neutral' and cut its target price from 600 to 340 Danish kroner, warning that competitive and compounding pressures are 'here to stay.' Market opinion is divided. Some analysts foresee additional downside, while others highlight support near $47.50 as a potential stabilization point. Contributors on Seeking Alpha argue that the sell-off may have priced in worst-case scenarios, leaving room for a measured recovery if Novo's R&D pipeline delivers next-generation weight-loss drugs or accelerates global expansion. Novo Nordisk started its journey in Denmark in the 1920s, when two small companies—Nordisk and Novo—were founded to make insulin for people with diabetes. In 1989, the two merged to form Novo Nordisk as we know it today. The company's largest owner is the Novo Nordisk Foundation, which holds nearly a third of the shares but controls more than three-quarters of the voting rights. Headquartered in Bagsværd, just outside Copenhagen, Novo Nordisk has grown into one of the world's most valuable pharmaceutical companies. In mid-2025, it's worth around $305 billion, although last year it briefly touched almost $600 billion, putting it among the most valuable companies on the planet. At home, its impact is hard to overstate. Novo Nordisk is Denmark's biggest taxpayer, a major exporter, and an economic powerhouse—at one point its market value was larger than Denmark's entire GDP. Today, it's not just a national success story but a global leader in diabetes, obesity, and rare disease treatments. Despite short-term headwinds, Novo Nordisk is pursuing multiple growth avenues: Amycretin – Dual-Action Obesity Drug: Phase 1b/2a trials show 22% average body weight loss over 36 weeks, sparking a ~12% stock bump. CagriSema – Record Weight Loss in Phase III: Achieved 20.4% weight reduction in obese adults and 13.7% in type 2 diabetes patients. Oral Semaglutide & Amycretin: Oral formulations are under U.S. regulatory review, potentially broadening adoption. $2.2B Septerna Partnership: Four programs targeting obesity, type 2 diabetes, and cardiometabolic diseases. Insulin Icodec (Awiqli) – Once-Weekly Insulin: Approved in Canada, EU, and Japan, improving patient adherence. NNC2215 – Glucose-Sensitive 'Smart' Insulin: Adjusts activity based on blood sugar, reducing hypoglycemia risk. Alhemo (Concizumab) – Hemophilia Treatment: FDA-approved July 2025 for A and B types. AI and Rare Disease Expansion: Collaborations with Heartseed, Ventus Therapeutics, and megaTAL platform targeting cardiovascular, MASH, and CKD therapies. These developments suggest Novo's core capabilities remain strong, providing potential long-term catalysts. Not exactly. While Novo Nordisk faces heightened competition, slowing growth, leadership changes, and legal pressures, it retains robust cash flows, a dominant market footprint, and a promising pipeline. Short-term turbulence is clear. Yet a full-scale Nokia-style collapse is unlikely given Novo's strategic assets and global reach. The company is navigating a near-term storm, but its innovation engine and expansion efforts leave the door open for recovery. Indicator Status Sales & Profit Guidance Significantly lowered; investor reaction strongly negative Competition & Market Threats Rising; compounded drugs and Eli Lilly products erode share Leadership & Strategy New CEO; strategic clarity still evolving Legal & Regulatory Risks Class-action lawsuit; compounding disputes add uncertainty Valuation & Sentiment Deeply discounted; mix of caution and opportunistic value Long-term Outlook Not terminal; pipeline and global expansion offer growth levers Defensive stance: Exercise caution until guidance execution and competitive dynamics are clearer. Exercise caution until guidance execution and competitive dynamics are clearer. Value opportunity: Contrarian investors may view the sharp dip as a long-term buying chance, particularly if Novo can regain share and deliver on pipeline milestones. Contrarian investors may view the sharp dip as a long-term buying chance, particularly if Novo can regain share and deliver on pipeline milestones. Catalysts to watch: CEO performance, legal outcomes, regulatory action on compounding, and international R&D breakthroughs. Novo Nordisk is at a critical crossroads. The company isn't collapsing, but it's clear that the weight-loss and diabetes markets are no longer uncontested territory. How the company navigates competition, regulation, and innovation in the coming months will determine whether this is a temporary stumble—or the start of a deeper transformation. Q1: What caused the Novo Nordisk stock plunge recently? A1: The stock fell after 2025 sales guidance cuts and rising competition from Eli Lilly drugs and compounded versions. Q2: How is Wegovy Ozempic market pressure affecting Novo Nordisk? A2: Competing drugs and pharmacy compounding have reduced market share and investor confidence.
Hans India
13 hours ago
- Hans India
IBM unveils new India Client Experience Centre in Mumbai and announces plans to support Government of Maharashtra's Quantum Initiatives
Today, IBM (IBM: NYSE) announced the opening of the company's new IBM India Client Experience Center in Mumbai. As part of the facility's mission to support Indian enterprises' use of AI, hybrid cloud, and quantum computing, the company has signed a Letter of Intent (LOI) with the Government of Maharashtra to identify opportunities of support for the state's quantum initiatives. The LOI outlines areas of exploration that may include providing insight, knowledge, and expertise the state may use to help craft its own quantum initiative, and contributing to the development of the state's quantum ecosystem through workshops and other skills development efforts. Inaugurating the center, Shri Devendra Fadnavis, Hon'ble Chief Minister of Maharashtra said, 'With AI, quantum computing, and semiconductors, we are building a Viksit Maharashtra and Viksit Bharat. These technologies can accelerate sustainability and efficiency across sectors, creating new opportunities for growth and progress. Through our collaboration with IBM, we will harness quantum innovation to transform lives, while building a skilled talent pool to democratize its benefits and make them accessible to every citizen of the state.' Hans Dekkers, General Manager, IBM Asia Pacific said, 'IBM India Client Experience Centre reinforces our commitment in helping advance India's journey in AI, hybrid cloud, and quantum computing. Our interest in helping the Government of Maharashtra build their own vibrant quantum ecosystem exemplifies our commitment.' 'IBM welcomes the opportunity to engage with the Government of Maharashtra on advancing quantum computing skills in the state, in alignment with the country's National Quantum Mission, and vision of Viksit Bharat,' said Sandip Patel, Managing Director, IBM India and South Asia.
India Today
a day ago
- India Today
Bullish crypto exchange soars to $13.2B in NYSE debut
Cryptocurrency exchange operator Bullish BLSH.N was valued at about $13.16 billion after its shares more than doubled in their NYSE debut on Wednesday, underscoring investor confidence in the sector and lifting prospects for future U.S. listings by other digital asset parent of crypto news website CoinDesk raised $1.11 billion in its IPO, valuing the company at $5.4 billion — another sign of mainstream adoption in a market that recently topped $4 came out with an attractive initial valuation, and investors responded by aggressively bidding it up during the pre-IPO process," said Jeff Zell, senior research analyst at IPO Boutique. The stock opened at $90 and was trading over 150% its IPO price of $37 in afternoon trading. It went as high as $118, before paring gains slightly to trade at $92.60.A string of regulatory wins under a pro-crypto White House, corporate treasury adoption and ETF inflows have prompted investors to embrace the once-scorned digital asset class, driving bellwether bitcoin BTC= to record operator Gemini and asset manager Grayscale are also among the crypto firms that have confidentially filed to go public."We've gone public today, and there's a slew of others that are going to follow us, and I think that is net beneficial, because it gives people more options in terms of how they access this asset class," Bullish President Chris Tyrer told Reuters in an is close to concluding a two-year process to obtain a virtual currency license known as a "BitLicense" in New York, which would allow the company to operate in the state, Tyrer BitLicense requires companies to comply with requirements related to know-your-customer, anti-money laundering and Thiel-backed Bullish plans to convert a significant portion of the IPO proceeds to stablecoins — a slice of the crypto space that has boomed since U.S. President Donald Trump signed the Genius Act, creating a regulatory regime for the dollar-pegged FOCUSBullish's debut marks a rare U.S. listing by a crypto exchange, joining larger retail-focused rival Coinbase COIN.O, which became the first crypto player to be included in the benchmark S&P 500 .SPX index in in 2020, Bullish targets institutional clients, whose crypto holdings are expected to rise as a new White House order aims to allow alternative investments in 401(k) retirement plans."A pure institutional strategy positions Bullish for more stable, recurring revenue than exchanges reliant on retail volumes, which tend to be cyclical and sentiment-driven," said Michael Hall, co-chief investment officer and founding partner at Nickel Digital Asset CEO Tom Farley was previously the president of the a sector still overcoming reputational headwinds, that kind of leadership experience can be a differentiator in securing institutional mandates," Hall said.- Ends
